MarkARubinMD

PubMed

• 323 citations
  Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
  John R. Prensner, Mark A. Rubin, John T. Wei, Arul M. Chinnaiyan
  Science Translational Medicine. 2012-03-28
• 1568 citations
  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
  Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop
  The New England Journal of Medicine. 2015-10-28
• 631 citations
  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.
  Sooryanarayana Varambally, Jianjun Yu, Bharathi Laxman, Daniel R. Rhodes, Rohit Mehra
  Cancer Cell. 2005-11-01

Journal Articles

• Transcriptomic Heterogeneity in Multifocal Prostate Cancer  
  Mark A. Rubin, Aaron M. Udager, Nicole E. Curci, Simpa S. Salami, Scot A. Tomlins, The Journal of Clinical Investigation
• Publisher Correction: Suppression of Insulin Feedback Enhances the Efficacy of PI3K Inhibitors  
  Siddhartha Mukherjee, Marcus D Goncalves, Mark A Rubin, Nature
• Suppression of Insulin Feedback Enhances the Efficacy of PI3K Inhibitors  
  Marcus D Goncalves, Siddhartha Mukherjee, Mark A Rubin, Nature
• A comparative study of ERG status assessment on DNA-, mRNA-, and protein levels using unique samples from a Swedish biopsy cohort  
  Svensson MA, Perner S, Ohlson AL, Day JR, Groskopf J, Kirsten R, Sollie T, Helenius G, Anderseeon SO, Demichelis F, Andren O, Rubin MA, Diagn Mol Pathol, 1/1/2014
• Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing  
  Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J et al, Nat Biotechnol, 10/20/2013
• Frequent truncating mutations of STAG2 in bladder cancer  
  Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA,..., Nat Genet, 10/13/2013
• Racial differences in withdrawal of mechanical ventilation do not alter mortality in neurologically injured patients  
  Rubin MA, Dhar R, Diringer MN, J Crit Care, 10/8/2013
• Integrative annotation of variants from 1,092 humans: application to cancer genomics  
  Khurana E, Fu Y, Colonna V, Mu XJ, Kang HM, Lappalainen T, Sboner A, Lochovsky L et al, Science, 10/4/2013
•  
  Barbieri CE, Sboner A, Rubin MA, Garraway LA, J Pathol, 10/1/2013
• The mutational landscape of prostate cancer  
  Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA, Eur Urol, 10/1/2013
• Somatic copy number alterations by whole exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer  
  Menon R, Deng M, Ruenauver K, Queisser A, Offermann A, Boehm D, Vogel W, Scheble V, Fend F, Kristiansen G, Wernert N, Oberbeckmann N, Biskup S, Rubin MA, Shaikhibrahim..., J Pathol, 9/23/2013
• Variants at IRX4 as prostate cancer expression quantitative trait loci  
  Xu X, Hussain WM, Vijai J, Offit K, Rubin MA, Demichelis F, Klein RJ, Eur J Hum Genet, 9/11/2013
• Molecular characterization of prostate cancer following androgen deprivation: The devil in the details  
  Barbieri CE, Rubin MA, Eur Urol, 8/30/2013
• Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma  
  Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD, Genes Chromosomes Cancer, 8/1/2013
• Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2  
  Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR, Oncogene, 7/29/2013
• V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in pros...  
  Park K, Chiu YL, Rubin MA, Demichelis F, Mosquera JM, Hum Pathol, 7/12/2013
• Comprehensive molecular characterization of clear cell renal cell carcinoma  
  The Cancer Genome Atlas Research Network; Analysis working group: Baylor College of Medicine, Creighton CJ, Morgan M, Gunaratne PH,…Weill Cornell Medical College, Mosq..., Nature, 7/4/2013
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer  
  Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG, Urol Oncol, 7/1/2013
• Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma  
  Bhalla R, Kunju LP, Tomlins SA, Christopherson K, Cortez C, Carskadon S, Siddiqui J, Park K, Miguel Mosquera J, Pestano GA, Rubin MA, Chinnaiyan AM, Palanisamy N, Mod Pathol, 6/1/2013
• Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer  
  Schaefer G, Mosquera JM, Ramoner R, Park K, Romanel A, Steiner E, Horninger W, Bektic J, Ladurner-Rennau M, Rubin MA, Demichelis F, Klocker H, Prostate Cancer Prostatic Dis, 6/1/2013
• Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma  
  Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, Wexler LH, Laquaglia MP, Edelman M, Sreekantaiah C, Rubin MA, Antonescu CR, Genes Chromosomes Cancer, 6/1/2013
• Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity  
  Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, Macdonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA, Eur Urol, 5/1/2013
• Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover  
  Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW..., Proc Natl Acad Sci USA, 4/23/2013
• Identifying an ERG-positive subclass with clinical progression using expression profiling  
  Sboner A, Rubin MA, Eur Urol, 3/26/2013
• Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course  
  Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G, Int J Cancer, 2/15/2013
• Join now to see all

Books/Book Chapters

• Textbook of Genitourinary Oncology. 
  Chapter: Prostate cancer: molecular pathology and biologic determinants. 
  Rubin MADr. Nicholas Vogelzang2007

Lectures

• Cancers associated to ETS transcription factor translocations. 
  Italy - 11/1/2013
• Pathways to Therapy. 
  5/1/2013
• Embracing Excellence in Prostate, Bladder and Kidney Cancer. 
  Barcelona, Spain - 11/1/2012
• "Distinguished Lecture" Seminar Series. 
  Heidelberg, Germany - 5/1/2012
• Strategies to define novel prostate cancer target for therapy. 
  Leuven, Flanders, Belgium - 5/1/2012
• Frontiers in Cancer Prevention. 
  10/1/2011
• Diagnosing Significant Prostate Cancer. 
  Switzerland - 6/1/2011
• Systems Biology of Prostate Cancer. 
  Berlin, Germany - 10/1/2010
• EDRN Prostate Cancer Biomarker Program and Testing Opportunities. 
  7/1/2010
• Genetic and Molecular Predictors in Genitourinary Malignancies - Pathway Signatures in Genitourinary Malignancies. 
  6/1/2010
• Next Generation View on the Early Detection of Prostate Cancer. 
  1/1/2010
• Discovery of Recurrent Prostate Cancer Gene Fusions: Biological and Clinical Implications. 
  New York, NY - 6/1/2008
• Prostate Cancer. 
  San Diego, CA - 4/1/2008
• Gene Fusion in Prostate Cancer. 
  Milan, Italy - 3/1/2008
• Emerging Technology that are Improving Diagnosis and Therapy. 
  Tucson, AZ - 3/1/2008
• TMPRSS2-ETS Fusion Prostate Cancer Emerging Clinical Implications. 
  Denver, CO - 3/1/2008
• Pathology and clinical implications of gene fusion prostate cancer. 
  Cambridge, MA - 2/1/2008
• TMPRSS@-ERG Prostate Cancer: The most Common recurrent Gene Fusion and Biologic and Clinical implications. 
  1/1/2008
• Origins of Prostate Cancer: Understanding Molecular Heterogeneity 
  1/1/2008
• Clinical and Biological implications of TMPRSS2-ETS fusion prostate cancer. 
  Barcelona, Spain - 11/1/2007
• Molecular Biomarkers for Solid Tumors. 
  Los, Angeles, CA - 11/1/2007
• Molecular Basis of Prostate Cancer TMPRSS2-ERG Prostate Cancer: New Insights in prostate cancer heterogeneity Scientific Retreat. 
  Lake Tahoe, NV - 10/1/2007
• TMPRSS-ETS in Prostate Cancer: An update on clinical and pathologic Implications. 
  10/1/2007
• Current trends in GU Malignancies. 
  New York, NY - 10/1/2007
• Interfacing Animal Models with Human Cancer Biomarker Development. 
  Rockville, MD - 7/1/2007
• Join now to see all